Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir‐based dual combinations

Abstract

AbstractObjectivesThe availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)‐based two‐drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG + DOR compared with DTG/3TC and DTG/RPV and the rate of virological failure and target not‐detected maintenance over time.MethodsThis retrospective, monocentric analysis included all subjects who started a DTG‐based 2DR from 2018 to 2022 as a simplification. Descriptive statistics and non‐parametric tests to describe and compare the groups were applied. Kaplan–Meier probability curves and Cox regression models for regimens durability were used.ResultsThe study enrolled 710 individuals: 499 treated with DTG/3TC, 140 with DTG/RPV, and 71 with DTG + DOR. A 2DR with DOR was prescribed to older subjects who had a longer infection, greater exposure to different antiretroviral regimens, a higher proportion of resistance‐associated mutations, and a worse immune‐virologic status. Over a cumulative follow‐up of 68 152 weeks, 42 discontinuations were registered (5.9%). DTG + DOR had a risk of treatment interruption of 7.8% at 48 weeks and 9.8% at 96 weeks, significantly higher than the other 2DRs. In the multivariate Cox model, DTG + DOR and DTG/RPV were significantly associated with discontinuation. The maintenance of target not detected during follow‐up was similar among groups. The rate of virological failure was higher for DTG + DOR through different event definitions.ConclusionsDTG + DOR durability was high over a long follow‐up albeit lower than for other 2DRs. This combination might be an effective option in people with HIV that has proven difficult to treat.